News
InteRNA Technologies Announces Dosing of First Patient in First-in-Human Trial of microRNA Drug Candidate INT-1B3 in Patients with Advanced Solid Tumors
February 16, 2021
-- Phase 1 study to investigate safety and preliminary efficacy of lead candidate, INT-1B3 --
Read more
Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
February 12, 2021
Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Read more
InteRNA Technologies Extends Series B Financing Round Totaling EUR 18.5M
February 09, 2021
-- Proceeds to advance clinical evaluation of lead candidate INT-1B3 and further preclinical drug candidates towards the clinic --
Read more
First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals' Lead Immunotherapy ISA101b with Keytruda®
January 26, 2021
Combination aimed at priming and driving durable patient immune responses to cancer
Read more
Sapreme Appoints Henrik Luessen as Chief Business Officer
January 21, 2021
Appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer at Sapreme
Read more
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a...
Read more
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the eNRGy Clinical Trial
January 12, 2021
Merus N.V. today announced collaborations with nationwide medical organizations in the Netherlands and Japan to raise awareness...
Read more
ISA106 - SLP therapeutic for COVID-19
January 11, 2021
Interview with ISA Pharmaceuticals' CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cel...
Read more
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium
January 11, 2021
Clinical data from Phase 1 dose escalation study of MCLA-158 will be presented in a poster session at the American Society of C...
Read more
Macrophage Pharma expands Executive team with CSO and CTO
January 09, 2021
Key hires enhance management for next development phase
Read more
Klinische Fase 1a studie met lead compound INT-1B3
January 07, 2021
December 2020: Net voor Kerst in de bijlage van Het Algemeen Dagblad - InteRNA heeft klinische Fase 1a studie met lead compound...
Read more
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
January 07, 2021
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer
Read more
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
January 06, 2021
• First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2
• Evaluation of Cristal's CliCr® and I...
Read more
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors
December 17, 2020
Appointment of Björn Cochlovius, Ph.D. as Chairman of the Board
Read more
Sapreme Appoints Miriam Bujny as Chief Development Officer
October 27, 2020
Appointment of Miriam Bujny, Ph.D., as Chief Development Officer
Read more
Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients
October 15, 2020
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010in Treatment-Naïve Prostate Cancer Patients
Read more
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society
September 30, 2020
positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the O...
Read more
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform
September 29, 2020
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of sup...
Read more
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform
July 02, 2020
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop...
Read more
ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer
July 01, 2020
Primes the immune system to attack cancer cells in HPV16-positive cancers
Read more
